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Abstract Cancer-related fatigue is common, complex, and
distressing. It affects 70–100% of patients receiving
chemotherapy and a significant number who have completed
their treatments. We assessed a number of variables in
women newly diagnosed with primary breast cancer (BrCa)
to determine whether biological and/or functional measures
are likely to be associated with the development of clinically
significant fatigue (CSF). Two hundred twenty-three women
participated in a study designed to document the impact of
the diagnosis and treatment of primary breast cancer on
function. Forty-four had complete data on all variables of
interest at the time of confirmed diagnosis but prior to
treatment (baseline) and ≥9 months post-diagnosis. Objec-
tive measures and descriptive variables included history,
physical examination, limb volume, hemoglobin, white
blood cell count, and glucose. Patient-reported outcomes
included a verbal numerical rating of fatigue (0–10, a score
of ≥4 was CSF), five subscales of the SF-36, Physical
Activity Survey, and Sleep Questionnaire. At baseline, the
entire cohort (n=223) and the subset (n=44) were not
significantly different for demographic, biological, and self-
reported data, except for younger age (p=0.03) and ER+
(p=0.01). Forty-five percent had body mass index (BMI)≥
25, 52% were post-menopause, and 52% received modi-
fied radical mastectomy, 39% lumpectomy, 52% chemo-
therapy, 68% radiation, and 86% hormonal therapy.
Number of patients with CSF increased from 1 at baseline
to 11 at ≥9 months of follow-up. CSF at ≥9 months
significantly correlated with BMI≥25, abnormal white
blood cell count, and increase in limb volume and
inversely correlated with vigorous activity and physical
function (p<0.05). Fatigue increases significantly follow-
ing the treatment of BrCa. Predictors of CSF include high
BMI and WBC count, increase in limb volume, and low
level of physical activity. These are remediable.
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Function
Introduction
Cancer-related fatigue (CRF) is a clinical entity character-
ized by tiredness or exhaustion not necessarily precipitated
by activity; or when associated with activity, the severity
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DOI 10.1007/s00520-010-0986-7and duration of the fatigue are out of proportion to the level
of exertion [1, 2]. It is distressing and persistent and
interferes with mental and physical function. Fatigue is
frequently experienced by patients and survivors, regardless
of the type of cancer or its treatment [3, 4]. Fatigue is
considered pathological when it persists for several months
or is not relieved by rest. There is a wide range of its
prevalence, but overall, 48% (AHRQ Evidence Reports 02-
E032) of patients with cancer report fatigue. CRF is a
nearly universal symptom among those receiving anti-
neoplastic therapy [3–5]. Prevalence is particularly high in
women with breast cancer (BrCa) [6]. CRF may result from
the tumor itself or antedate its treatment. It is more likely to
be a side effect of primary cancer treatment, with reports of
prevalence as high as 70–100% as reported by the National
Comprehensive Cancer Network. (NCCN) (http://www.
nccn.org/professionals/physician_gls/f_guidelines.asp)
CRF is one of the most distressing symptoms associated
with cancer and its treatment [2]. Despite the functional
impact of the symptom and its relatively high frequency, its
pathophysiology is still not completely understood. The
predictive value of physical, functional, and laboratory-
measure abnormalities has not been demonstrated, in part
because most published work is retrospective and correlative.
There have been several reports documenting associations
between CRF and low hemoglobin [7], high neutrophil count
[8], high circulating levels of T lymphocytes [9], elevated
levels of inflammatory cytokines [10], and abnormal diurnal
cortisol levels [11, 12]. This suggests that CRF has, in part, a
biological basis, which may include regulation of immune
function. Other studies have identified associations with sleep
disturbances [13–15]. Biological factors are important con-
tributors to CRF, but fatigue is multi-factorial and likely to be
explained in terms of a bio-psychosocial and lifestyle model.
This view influenced our decision to determine whether
some of the variables associated with fatigue might be
predictive. In other words, a prospective approach, using
repeatedmeasuresthattestedsomeofthesesamevariablesand
added measures of physical function, might establish a profile
of an individual likely to develop clinically significant CRF.
Fatigue negatively influences participation in activity
and exercise and has undesirable health consequences,
correlated with tumor recurrence and mortality in BrCa
patients [16–18]. In addition, aerobic exercise has been
shown to be an effective treatment for mitigating CRF, as
long as it targets 75% or more of heart rate for 3 h/week
[19–24]. This is not to imply that only aerobic exercise
mitigates CRF; anaerobic exercise and relaxation training
have shown benefit as well [19, 20, 23–25]. This level of
effort is considered exercise, rather than activity. The
NCCN Practice Guidelines detail recommendations, which
include exercise, for treating CRF based on published data
and clinical experience (www.nccn.org).
We hypothesized that cancer survivors with CRF have
both biological abnormalities, such as high body mass index
(BMI) and blood counts and behavioral abnormalities such
as altered physical activity and sleep. We report the findings
of a prospective, repeated-measures, natural history study of
women with primary BrCa, receiving standard treatment.
The study was designed to compare patient descriptors and
biological measures with self-reports of fatigue, level of
physical activity, and daily routines over time. Our goal was
to develop a profile of individuals newly diagnosed with
BrCa who have clinically significant cancer-related fatigue
and use this to help identify who might be at considerable
risk for developing clinically significant CRF.
Patients and methods
A prospective, observational IRB-approved study (NIH 02-
CC-0044; National Naval Medical Center (NNMC) B01-052),
conducted at the NNMC Breast Care Center (Bethesda, MD)
from 2001 to 2006, utilized a surveillance model to identify
BrCa-related morbidity. All women newly diagnosed with
unilateral, early stage BrCa (stages I–III) were screened by a
physical therapist pre-operatively to determine eligibility and
signed a consent-to-participate form. Patients were excluded if
they were less than 18 years of age, had a previous history of
BrCa, bilateral BrCa, or prior severe trauma or surgery of the
upper limb (UL) on which the BrCa diagnosis had been made.
All subjects who met the inclusion criteria and agreed to
participate were consented prior to participation (n=223) and
were assessed at the pre-operative visit and reassessed at 1, 3,
6, 9, 12, 18, and 24 months post-operatively. The surveillance
model clinical pathway we use is illustrated in Fig. 1.F u r t h e r
information was retrieved from the patients’ medical records
including demographic and anthropometric measures, tumor
characteristics, data from routine blood draws and self-reports
Post Operative Surveillance - 3 month intervals
Breast Cancer Diagnosis 
Physical Therapy Surgery Med. Onc. Rad. Onc.
Pre-Operative Multi-Disciplinary 
Staging and Plan of Care
Blood tests
Limb volume
Self - reports of 
symptoms, health 
status, and activity
Fig. 1 Surveillance plan
1582 Support Care Cancer (2011) 19:1581–1591of function and physical activity. Types of treatments received
are as follows: 23 received modified radical mastectomy, 17
lumpectomy, 23 chemotherapy, 30 radiation, and 20 hormonal
therapy. There were 31 who had axillary nodal dissection, 12
who had sentinel node sampling, and one who had neither.
Descriptive statistics for baseline findings, which were
complete for 44 participants, are presented in Table 1.
On initial visit for study purposes and at ≥9-month visits,
patients were asked if they experienced fatigue, and if so,
they were asked to quantify verbally their level of fatigue at
the time of clinic visit, scoring the intensity from 0 (no
fatigue) to 10 (maximum fatigue). The fatigue measure
used was a verbal numerical rating (VNR). The designation
of clinically significant fatigue (CSF) was set at ≥4, based
on the work done by Temel, et al. [26].
At the 9-month and subsequent visits, all patients were
given the Medical Outcomes Study Short Form 36 (SF-36)
[27], from which we analyzed four subscales and two
composite scales, including the physical function, vitality,
mental function, and social function subscales and the
physical function and mental function total composite.
These scales have been validated, and norms have been
established. A score of 50 is considered normal. Higher
scores represent responses above (better than) the mean. All
participants completed the Harvard Alumni Health Study
Physical Activity Survey (PAS) [28, 29]. The PAS is a self-
report of the amount of time spent (in hours) performing
physical activities, rated as vigorous, moderate, and mild. It
was developed from epidemiological data gathered over a
40-year period from Harvard Alumni. The PAS asks
respondents to enter the variety of activity in which they
participate and uses an established coding system to assess
the rate at which energy is expended, thereby determining
the level of exercise intensity. They completed the
Pittsburgh Sleep Quality Index which was used to record
the number of hours spent sleeping [30].
At each visit, participants underwent optical scanning of
the upper extremities to assess limb volume and possible
change over time [31]. Measurements for both upper limbs
were taken in a standard position with the Perometer®.
1 UL
volume was calculated using 80% of the total limb length,
measured from the ulnar styloid process to the tip of the
acromion, for standardization. Body weight was taken at
each visit to control for weight change. Diagnostic criteria
for lymphedema was a volume increase in the affected UL
volume of at least 3% (100 cm
3), compared to the subject’s
pre-operative measurement and with consideration of the
contralateral limb volume changes. The technique used was
that reported in a previous study [31, 32].
Data collection
All subjects were recruited from NNMC-BCC. Subjects
were interviewed and evaluated by a physical therapist for
their initial (baseline) examination and for all follow-up
appointments. There were 223 subjects recruited to the
study; however, over the 5-year period of follow-up, only 44
had adequate follow-up data to be included. Table 1 displays
the variables of interest for the entire group (n=233) and
the subset we used for the analysis (n=44).
Statistical analyses
Analyses were performed on all 44 subjects for whom we had
complete data sets of the variables of interest. Spearman’s
correlation coefficients were used in all correlation analy-
ses, given the relatively small sample size and that some of
the variables are highly skewed. Correlation analyses were
performed between CSF, defined as ≥4 on the VNR, and
variables of interest. We performed logistic regression
analyses to assess the effects of baseline demographic and
biological variables on the VNR at 9 months and after. We
also performed simple linear regression analyses to assess
the effects of baseline demographic variables and biological
variables at 9 months and after and on variables which
measured function, including vigorous activity (PAS),
sleeping (PSQI), physical function, mental health, vitality,
and social function (SF-36). For all regression analyses, we
used forward model selection to select a model such that
no other variable met the 0.1 significance level for entry
into the model. All data analyses were conducted using
SAS v 9.2.
Results
Forty-four women, out of a total population of 223 who had
enrolled in the study, had complete baseline and follow-up
data collected between 9 and 24 months available for
analysis of descriptive variables of interest (Table 1). All
baseline data available for the entire cohort and that which
were complete and acceptable for analysis for the follow-up
period are presented in Table 1. There were statistically
significant (p<0.05) differences in the variables for which
comparisons could be made between the entire cohort
(n=233) and the subjects reported in this study (n=44).
Statistically significant differences in the two groups were
demonstrated for age (study cohort is younger) and ER
positivity (study cohort has a greater number in this group).
Follow-up data were required to have been collected after
completion of primary treatment of BrCa.
Table 2 presents data on variables of interest and their
relationship to the presence of clinically significant fatigue
1 Perosystem, Messegerate, Wuppertal, Germany
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Support Care Cancer (2011) 19:1581–1591 1585at ≥9 months following diagnosis. Breast cancer treatments
are included, but none was significantly correlated with
CSF. We performed a logistic regression analysis on these
data. Entry into the model required statistical significance
for the variable at p≤0.10. The following remained
significant: menopausal status (odds ratio (OR) 10.65, p=
0.03), limb volume increase (OR for 100-cm
3 increase of
limb volume is 3.75, p=0.02), increased white blood cell
(WBC; OR 1.99, p=0.04). The amount of time spent
sleeping did not differ significantly between those with
CSF (n=11) and those without (n=33). The average for the
CSF group was 8.27 h per night and, for those without,
8.35 h per night.
Table 3 compares the variables of interest with selected
subscalesoftheSF-36.Theanalysiswasperformed,inpart,to
contrast the relationships among self-reported vitality, phys-
ical and mental status, and the variables of interest. Vitality is
often consideredthe inverse offatigue and often reportedwith
fatigue measures. We performed a linear regression analysis
on these data. Entry into the model required statistical
significance for the variable at p=<0.10. The following
remained significant and were all inversely related: having
children (p=0.06), menopausal status (p=0.01), and BMI
(p=0.01).
Discussion
The prospective, descriptive study from which these data
were collected was designed to identify the prevalence of
and risk factors for upper limb impairments and functional
limitations in women with the diagnosis of primary BrCa.
The study employed a surveillance model with repeated
measures over a 5-year period to enable identification of
variables the investigators believed would influence func-
Table 2 Correlation between selected variables and clinically
significant fatigue at ≥9 months after baseline measures
N=44 Coefficient
Demographics, baseline
Age 45 and below −0.243
Race/ethnicity
White 0.076
African American 0.000
Other −0.126
Married 0.000
Has any child 0.108
Biological variables, baseline
Baseline
BMI>=25 0.422***
Reached menopause 0.236
Tumor size 0.050
Number of positive nodes −0.308**
ER positive −0.183
Her2Neu positive −0.108
Hemoglobin, actual value 0.039
Hemoglobin>=11 0.156
Glucose, actual value 0.197
Glucose>=110 0.036
White blood cell, actual value 0.432***
White blood cell abnormal 0.360**
Affected limb volume −0.027
Biological variables, 9 months and after
BMI>=25 0.316**
Hemoglobin, actual value −0.079
Hemoglobin>=11 −0.183
Glucose, actual value 0.172
Glucose>=110 0.036
White blood cell, actual value 0.382**
White blood cell abnormal −0.033
Affected limb volume 0.188
Limb volume increase 100 cc or more 0.329**
Treatment variables
Type of surgery
Lumpectomy 0.189
Modified mastectomy −0.183
Simple mastectomy 0.000
Had chemotherapy −0.079
Had XRT −0.056
Had hormonal therapy −0.229
Functioning variables, 12 months and after
Vigorous activity
Time vigorous activity, weekday −0.314**
Time vigorous activity, weekend −0.125
Average time on vigorous activity (per day) −0.259*
Sleeping
Time sleeping weekday 0.063
Table 2 (continued)
N=44 Coefficient
Time sleeping weekend −0.036
Average time sleeping (per day) 0.051
Physical function
Physical function subscale −0.302**
Physical function total composite −0.161
Mental health
Mental health score 0.125
Mental health total composite −0.147
Vitality −0.176
Social function 0.106
Spearman correlation coefficients presented in the table. Clinically
significant fatigue is defined as fatigue score≥4
*p≥0.10; **p<0.05; ***p<0.01; ****p<0.001
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Support Care Cancer (2011) 19:1581–1591 1587tion over time. This approach was used to record at
specified intervals the signs and symptoms of physical
impairment, functional limitation, and fatigue. Previously
reported work using this model demonstrates that prospec-
tive surveillance and early intervention in women with
breast cancer resulted in successful identification and
treatment of lymphedema [32].
The measurement of fatigue has posed significant
methodological difficulties for investigators. There is no
consensusonwhich measure shouldbeused,althoughrecent
opinions have been published that propose criteria for what
constitutes acceptable fatigue measures; and several have
been shown to be particularly suitable for evaluating cancer
patients [33–35]. Frequently, health care providers do not
assess patients for the presence of fatigue or seek to
determine contributors to fatigue and often do not prescribe
effective treatments [36]. Effective treatment begins with
the identification of the undesirable process or syndrome
and includes determination of its possible contributors.
We chose to use a unidimensional verbal report of
fatigue because it was easy to administer in a busy clinic. It
is sensitive to change and, although not specific to CRF, has
been validated against commonly used fatigue measures in
cancer patients and patients with rheumatic disease [26,
37]. The selection of a value of “4” as clinically significant
was based on the NCCN guidelines and has been confirmed
as being valid [26]. We also used a measure of vitality,
included as a subscale of the SF-36, which has been used
frequently as an indicator of fatigue in cancer survivors.
This is a self-report about whether an individual feels
“energetic.” Some investigators have suggested that this
scale measures central fatigue and reflects a combination of
mood and motivation and is not a strong indicator of either
peripheral fatigue or aerobic fitness [38]. In the study
reported here, we demonstrate correlation between high
vitality scores and less sleep, and increase in hemoglobin
and vigorous activity.
Patients in this cohort report a 25% incidence of CSF at
least9monthsafterthediagnosisofBrCaismadeandconfirm
the observation that fatigue in cancer survivors is prevalent
andpersistsafterprimarytreatmentiscompleted.Thefindings
are somewhat lower than several studies reporting CRF but
aregenerallyconsistentwiththepublishedexperienceofother
investigators [1–7, 39]. Explanations for these differences
include the relatively low average age of this cohort
(50.5 years) and some are active duty military or military
dependents and many are in the work force.
This study reports data that correlates of persistent
clinically significant CRF include number of positive
nodes, increase in limb volume, high BMI, an increase in
WBC count over baseline to >8,000, and low level of
physical activity and physical function. We extend these
observations and suggest that a BMI≥25, WBC>8,000,
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1588 Support Care Cancer (2011) 19:1581–1591and increase in limb volume are predictive of fatigue. This
study does not establish the causal relationship among these
variables and CSF in cancer survivors, rather it establishes
that women likely to have CSF following BrCa diagnosis
and treatment are likely to demonstrate these findings.
CRF has been shown to correlate with several factors,
including anemia, inflammatory cytokines, cortisol, and
obesity [7–17, 40–43]. We included some of these variables
for measurement in this study and added outcomes that
measure physical activity and function. The rationale behind
this is that physical activity, particularly strenuous physical
activity (>5METS), is likely to have a beneficial outcome for
breast cancer patients. Women who do not participate in
strenuous physical activity have been shown to have less
good clinical outcomes. Exercise has been associated with
improved outcomes in women with BrCa [17, 19–21, 44, 45]
and has been demonstrated to have a significant effect in
improving CRF [21–25] and also has been shown to improve
glucose uptake and insulin sensitivity [16]. Possible mech-
anisms for decreased prevalence of CRF and good health
outcomes in women with BrCa who are physically active
pertain to the effect of exercise and activity on a variety of
critical pathways that impact metabolism and inflammation.
These include decrease in serum pro-inflammatory cytokines
[41], mobilization of visceral fat, and increased insulin
sensitivity and glucose uptake [16]. These are of specific
benefit to women with BrCa diagnoses because of the
adverse associations between obesity and BrCa [17, 18], and
recurrence and mortality from BrCa associated with obesity
[18]. Physical activity has been reported to help regulate
sleep and diurnal variation of cortisol [46–49]. The amount
of time spent sleeping was not significantly different between
the two groups in this study.
The data summarized in Table 3 were selected to
demonstrate which functional measures (physical, mental,
or vitality) correlate with the variables of interest. Addi-
tionally, we included these data to present comparative data
among the subscales of the SF-36 but also to point out
differences between the vitality subscale and the others. Of
note, the less time spent sleeping, the higher are the
subscale scores on the SF-36.
The focus of this paper is to identify clinical and
biological variables likely to be associated with persistent,
clinically significant fatigue in BrCa survivors. However, it
is tempting to cluster the findings reported here into a
speculative hypothesis that those with CSF may have a pro-
inflammatory state. The high BMI and its increased burden
of inflammatory adipocytes and the elevated WBC,
combined with an increase in limb edema, may all be
contributing to an inflammatory state. This concept has
been supported by publications of retrospective studies in
which pro-inflammatory cytokines are associated with the
presence of CRF [10, 40, 50]. Lymphedema may be an
inflammatory transudate, and the fluid itself may be high in
pro-inflammatory cytokines [51]. These inflammatory
cytokines have been implicated in other illnesses associated
with fatigue, some of which have affective components, as
well [52, 53]. The “clustering” of BMI, limb edema, and
elevation of WBC reported here suggests that inflammatory
as well as metabolic factors may be contributing to CRF.
Other investigators have established an important role for
the presence of low hemoglobin in CRF [7, 54]. We did not
find a correlation between a decrease in hemoglobin and
fatigue. We did identify a significant benefit to patients who
had a rise in hemoglobin from baseline, as measured by
physical, mental, and vitality scores of the SF-36 subscales.
Many of the variables we chose to explore in this study
have been shown to be contributors to CRF in the BrCa
population [55]. Weconfirmsomeandaddtothesepredictors
including number of positive lymph nodes, reaching meno-
pause, presence of high BMI, increase in limb volume,
increase in WBC, and low level of vigorous and physical
activity. The regression analysis of these data suggest that the
presence of menopause, increase in WBC count, and limb
volume of >100 cm
3 are significant predictors for CSF
fatigue in this population. Several of the abnormalities
identified here, which are associated with low levels of
activity, can be addressed through rehabilitation and medical
management to prevent, mitigate, or reverse CSF.
There are several limitations to the study we report here.
We recruited 223 participants in this prospective study. We
report complete data on 44. The fact that we have repeated
measures on all variables in only 22% is a result of a
number of factors: (a) some did not complete the original
baseline data; (b) this group of subjects is a highly mobile
population due to military deployment and transfer to other
locations; (c) completion of the questionnaires was time
consuming and patients were often busy seeing multiple
providers at the same clinic setting.
We have tried to address the issue of dropouts by
presenting and analyzing the data in such a way that
comparisons can be made between the entire cohort and the
subgroup of 44 in the final cohort. The whole group is
similar to the subset we report on all variables reported, as
we displayed in Table 1.
Another difficulty with the study is that there is a small
number of participants, but we are interested in a large
number of variables, across many domains, including
anthropometric and biological measures, demographic
descriptors, activity level, and sleep. In order to reduce
the likelihood of bias, we used a prospective design and
non-parametric, Spearman rank order statistical analytic
approach. We were fortunate to have been able to evaluate
and treat patients in the same setting, with only a few care
providers utilizing a standard staging procedure and offer
patients a prescribed regimen based upon their BrCa stage.
Support Care Cancer (2011) 19:1581–1591 1589Another difficulty we faced was the ability to capture
baseline data at a time when subjects were experiencing a
difficult time and facing uncertainty about their treatments
and future. Further, this occurred in a busy clinic. We
selected a unidimensional measure of fatigue, which has its
limitations. However, it has validity in cancer patients [26],
and its utility in identifying people with clinically signifi-
cant fatigue has been accepted. Finally, unidimensional
fatigue measures have been used to determine who needs
treatment in populations with cancer diagnoses.
Conclusion
A surveillance approach, using valid instruments and
repeated measures in patients with primary BrCa, is one
method that can be employed to identify clinically sig-
nificant CRF symptoms throughout the course of evaluation
and treatment of BrCa. The patient most likely to benefit
from this approach because of an increased risk for
developing CRF and CSF is one who is post-menopause
and overweight and has an increase in limb volume of more
than 100 cm
3 from baseline measures and an elevation in
WBC count.
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